Based on results of this trial, ramucirumab was approved in May 2019 by the FDA as a second-line agent for advanced HCC (after treatment with sorafenib) with alpha-fetoprotein (AFP) of ≥400 ng/mL [17]. The gene discussed is AFP; the disease is hepatocellular carcinoma.